Published in Gene Therapy Weekly, October 18th, 2001
Combination therapy, in effect, makes a good vaccine better. A.G. Niethammer and colleagues used a mouse-human antiganglioside GD2-interleukin (IL)-2 fusion protein (ch14, 18-IL2) to show that targeting IL-2 at the tumor microenvironment boosted immune response against murine melanoma when mice were administered oral DNA vaccines produced by fusing murine ubiquitin genes with murine melanoma peptide epitopes. Attenuated Salmonella typhimurium was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Gene Therapy Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.